title: Statin treatment decreases serum angiostatin levels in patients with ischemic heart disease.
abstract: OBJECTIVE
  Angiogenesis and chronic inflammation are known to be co-dependent in atherosclerosis and cardiovascular diseases. This study was undertaken to investigate whether simvastatin could affect serum levels of angiostatin, a potent endogenous inhibitor of neovascularization, in patients with ischemic heart disease (IHD).
  
  
  METHODS
  Twenty-six patients with clinically confirmed IHD and hypercholesterolemia were assigned 40 mg/day of simvastatin for 8 weeks. Levels of lipid metabolism, C-reactive protein (C-RP) and other biochemical parameters in serum samples were measured using biochemical analyzer. Serum angiostatin levels were determined by Western blot. Association of serum angiostatin levels with total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and C-RP levels was evaluated.
  
  
  RESULTS
  Simvastatin therapy improved the main parameters of lipid metabolism, including statistically significant (P < 0.05) reductions in TC (by 46%) and LDL-C (by 42%), and decreased inflammatory marker C-RP (by 32%), as compared with the baseline. Simvastatin treatment resulted in marked reduction of serum angiostatin level (by 80% in comparison with baseline, P < 0.05). Strong positive correlations between serum angiostatin level versus concentrations of TC, LDL-C, and C-RP were demonstrated before onset of the study (r = 0.48311, 0.6252, and 0.653, respectively) and after simvastatin therapy (r = 0.67752, 0.6485, and 0.8244, respectively).
  
  
  CONCLUSIONS
  We describe for the first time novel pleiotropic effect of statin therapy associated with decrease of serum angiostatin levels. Thus, circulating angiostatin represents an independent additional risk marker for cardiovascular events and could be applied as potential supplementary indicator for evaluation of statin therapy efficacy.
authors.affiliation: Department of Enzyme Chemistry & Biochemistry, Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, Kyiv, Ukraine. Electronic address: artem_tykhomyrov@ukr.net.
authors.forename: Artem A
authors.initials: AA
authors.lastname: Tykhomyrov
authors.affiliation: Department of Biophysics & Biochemistry, Dnipropetrovsk National University, Dnipropetrovsk, Ukraine.
authors.forename: Victor S
authors.initials: VS
authors.lastname: Nedzvetsky
authors.affiliation: Department of Hospital Therapy No. 1 and Occupational Diseases, State Establishment "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dnipropetrovsk, Ukraine.
authors.forename: Nataliia I
authors.initials: NI
authors.lastname: Bardachenko
authors.affiliation: Department of Enzyme Chemistry & Biochemistry, Palladin Institute of Biochemistry of National Academy of Sciences of Ukraine, Kyiv, Ukraine.
authors.forename: Tatiana V
authors.initials: TV
authors.lastname: Grinenko
authors.affiliation: Department of Hospital Therapy No. 1 and Occupational Diseases, State Establishment "Dnipropetrovsk Medical Academy of Health Ministry of Ukraine", Dnipropetrovsk, Ukraine.
authors.forename: Olexandr V
authors.initials: OV
authors.lastname: Kuryata
mesh_terms: D000368:Aged; D043168:Angiostatins / Q000097:blood*; D002097:C-Reactive Protein / Q000378:metabolism; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage*; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000097:blood / Q000188:drug therapy
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D043168:Angiostatins; D002097:C-Reactive Protein
keywords: Angiostatin; Atherosclerosis; C-reactive protein; Cholesterol; Ischemic heart disease; Lipoproteins; Simvastatin